“…Disadvantages include requirements for development and validation of assays as well as small volume of samples collected [Parker and Cubit, 1999]. Since its first implementation for the diagnosis of phenylketonuria in newborns in the 1960s [McDade et al, 2007], DBS has been used for the diagnosis of a number of metabolic disorders and for the analysis of a wide range of biomarkers [McDade et al, 2007], including antibodies raised against several viruses, such as the human immunodeficiency virus [Major et al, 1991; Castro et al, 2008], rubella virus [Punnarugsa and Mungmee, 1991; Neto et al, 1995; Helfand et al, 2001, 2007; Karapanagiotidis et al, 2005], measles virus [Helfand et al, 2001; Ridell et al, 2002], HTLV [Parker et al, 1995], Epstein‐Barr virus [Fachiroh et al, 2008], and hepatitis viruses [Villa et al, 1981; Gil et al, 1997; Tappin et al, 1998; De Almeida et al, 1999; McCarron et al, 1999; Desbois et al, 2009]. However, the use of DBS for the detection of antibodies to hepatitis A virus (anti‐HAV) has been limited [Gil et al, 1997; De Almeida et al, 1999; Desbois et al, 2009], and there are no studies which describe the use of DBS for assessing the humoral response after hepatitis A vaccination.…”